非霍奇金淋巴瘤CAR-T细胞治疗应答的炎症生物标志物特征
研究基于149例非霍奇金淋巴瘤患者构建无监督定量模型InflaMix,整合14项CAR-T输注前实验室与细胞因子指标,识别出与治疗失败高风险相关的炎症特征(死亡或复发HR 2.98,95%CI 1.60-4.91,P<0.001),并在3个独立队列共688例患者中验证。
要点
- InflaMix整合14项CAR-T输注前实验室与细胞因子指标,识别治疗失败高风险炎症特征。
- 高风险特征与死亡或复发风险升高相关:HR 2.98(95%CI 1.60-4.91,P<0.001)。
- 3个独立队列共688例验证,InflaMix可重复识别复发与死亡风险较高患者。
核心结论
- InflaMix是接受CAR-T治疗的非霍奇金淋巴瘤患者床旁临床决策的有价值工具。
研究设计与样本
- 开发队列为149例非霍奇金淋巴瘤患者,构建无监督定量模型InflaMix,整合14项CAR-T输注前实验室与细胞因子指标。
- 采用3个独立队列共688例来自不同治疗中心的非霍奇金淋巴瘤患者验证该模型。
主要发现
- InflaMix识别出与CAR-T治疗失败高风险相关的炎症特征,包括死亡或复发风险升高:HR 2.98(95%CI 1.60-4.91,P<0.001)。
- InflaMix在3个独立队列中一致且可重复地识别疾病复发与死亡可能性较高的患者。
- InflaMix在已建立的预后标志物(包括肿瘤负荷)之外提供补充预测价值。
- InflaMix在数据缺失情况下表现稳健,仅使用6项 readily available 实验室指标时仍保持准确性。
关键数值与推荐
- 高风险炎症特征与死亡或复发风险升高相关:HR 2.98(95%CI 1.60-4.91,P<0.001)。
临床怎么用
- InflaMix可用于接受CAR-T治疗的非霍奇金淋巴瘤患者的床旁临床决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disease progression is a substantial challenge in patients with non-Hodgkin lymphoma (NHL) undergoing chimeric antigen receptor T cell (CAR-T) therapy. Here we present InflaMix (INFLAmmation MIXture Model), an unsupervised quantitative model integrating 14 pre-CAR-T infusion laboratory and cytokine measures capturing inflammation and end-organ function. Developed using a cohort of 149 patients with NHL, InflaMix revealed an inflammatory signature associated with a high risk of CAR-T treatment failure, including increased hazard of death or relapse (hazard ratio, 2.98; 95% confidence interval, 1.60-4.91; P < 0.001). Three independent cohorts comprising 688 patients with NHL from diverse treatment centers were used to validate our approach. InflaMix consistently and reproducibly identified patients with a higher likelihood of disease relapse and mortality, and it provided supplementary predictive value beyond established prognostic markers, including tumor burden. Moreover, InflaMix exhibited robust performance in cases with missing data, maintaining accuracy when considering only six readily available laboratory measures. These findings show that InflaMix is a valuable tool for point-of-care clinical decision-making in patients with NHL undergoing CAR-T therapy.
引用
- Raj SS, Fei T, Fried S, et al. An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma. Nat Med. 2025. PMID: 40169864. doi:10.1038/s41591-025-03532-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。